Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bevacizumab
Bevacizumab is a substance that blocks formation of new blood vessels to treat certain cancers and eye conditions caused by abnormal vessel growth.
Regorafenib
Regorafenib is a substance that helps slow tumor growth by blocking signals cancer cells and the blood vessels feeding them need to grow.
Sacituzumab Govitecan
Sacituzumab govitecan is an antibody-based cancer treatment that targets tumor cells and delivers a cell-killing agent to shrink certain advanced cancers.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Charite Universitaetsmedizin Berlin KöR
Hematololgy, Oncology and Cancer Immunology
Berlin, Germany
Technische Universitaet Dresden
Studienzentrale Internistische Onkologie
Dresden, Germany
Krankenhaus Nordwest GmbH
Institut für Klinisch-Onkologische Forschung (IKF)
Eschborn, Germany

Sponsor: Universitaetsklinikum Heidelberg AöR
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.